Answers are grounded in this paper and cite their sources.
Nonspecific protein accumulation at material–biological interfaces can compromise biomedical device performance. This study investigated crosslinker-associated swelling and SDS-recoverable protein responses in 2-methacryloyloxyethyl phosphorylcholine (MPC)-based hydrogels. M85-BMEP and M85-EGDMA were prepared with the same MPC/ethyl methacrylate ratio (85/15, w/w), nominal crosslinker content (2 mol%), and polymerization conditions, differing only in crosslinker type: phosphate-containing bis[2-(methacryloyloxy)ethyl] phosphate (BMEP) or ethylene glycol dimethacrylate (EGDMA). M100-BMEP was included as an additional formulation. FTIR, EDX, SEM, and gravimetric swelling characterized the hydrogels; SDS-recoverable protein was quantified after exposure to BSA and 20-fold-diluted commercial human serum. In PBS, M85-BMEP and M85-EGDMA exhibited similar swelling ratios (5.23 ± 0.66 and 5.17 ± 0.74 g/g , respectively; p = 0.994 ), despite markedly different SDS-recoverable protein responses. External-area-normalized BSA recovery was 5.247 ± 0.325, 11.283 ± 0.534, and 20.300 ± 0.741 μ g cm − 2 , while serum-protein recovery (BSA equivalents) was 3.630 ± 0.426, 16.523 ± 0.794, and 21.617 ± 0.438 μ g cm − 2 for M100-BMEP, M85-BMEP, and M85-EGDMA, respectively. All pairwise comparisons of area-normalized protein recovery were significant in both environments ( p < 0.001 ). Within the matched M85 pair, M85-BMEP exhibited approximately 44% lower BSA recovery and 24% lower serum-protein recovery than M85-EGDMA, retaining the same ranking after dry-mass normalization. These findings highlight crosslinker selection as an important formulation variable for MPC-based hydrogel interfaces.
No takes yet. Share an insight, caveat, or question.
Coşkun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: